Erratum: Neuromedin U: A Small Peptide in the Big World of Cancer. Cancers 2019, 11, 1312

The authors wish to make the following corrections to this paper [1]:

The authors would like to replace references 23–40. The original references 23–40 are:

23.

Alevizos, I.; Mahadevappa, M.; Zhang, X.; Ohyama, H.; Kohno, Y.; Posner, M.; Gallagher, G.T.; Varvares, M.; Cohen, D.; Kim, D.; et al. Oral cancer in vivo gene expression profiling assisted by laser capturemicrodissection and microarray analysis. Oncogene 2001, 20, 6196–6204.

24.

Yamashita, K.; Upadhyay, S.; Osada, M.; Hoque, M.O.; Xiao, Y.; Mori, M.; Sato, F.; Meltzer, S.J.; Sidransky, D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, 2, 485–495.

25.

Tokumaru, Y.; Yamashita, K.; Osada, M.; Nomoto, S.; Sun, D.I.; Xiao, Y.; Hoque, M.O.; Westra, W.H.; Califano, J.A.; Sidransky, D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004, 64, 5982–5987.

26.

Wang, L.; Chen, C.; Li, F.; Hua, Q.Q.; Chen, S.M.; Xiao, B.K.; Dai, M.Y.; Li, M.; Zheng, A.Y.; Yu, D.; et al. Overexpression of neuromedin U is correlated with regional metastasis of head and neck squamous cell carcinoma. Mol. Med. Rep. 2016, 14, 1075–1082.

27.

Garczyk, S.; Klotz, N.; Szczepanski, S.; Denecke, B.; Antonopoulos, W.; Von Stillfried, S.; Knchel, R.; Rose, M.;Dahl, E. Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of theWNTsignaling pathway. Oncotarget 2017, 8, 36246–36265.

28.

Rani, S.; Corcoran, C.; Shiels, L.; Germano, S.; Breslin, S.; Madden, S.; McDermott, M.S.; Browne, B.C.; O’Donovan, N.; Crown, J.; et al. Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. Cancer Res. 2014, 74, 3821–3833.

29.

Harten, S.K.; Esteban, M.A.; Shukla, D.; Ashcroft, M.; Maxwell, P.H. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Mol. Cancer 2011, 10.

30.

Lin, T.Y.; Wu, F.J.; Chang, C.L.; Li, Z.Y.; Luo, C.W. NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling. Oncotarget 2016, 7, 10228–10242.

31.

Yang, X.Y.; Wang, C.C.; Lee, W.Y.W.; Trovik, J.; Chung, T.K.H.; Kwong, J. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 2018, 413, 23–34.

32.

Ketterer, K.; Kong, B.; Frank, D.; Giese, N.A.; Bauer, A.; Hoheisel, J.; Korc, M.; Klee, J.; Michalski, C.W.; Friess, H. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett. 2009, 277, 72–81.

33.

Zhang, S.L.; Wang, Q.; Han, Q.; Han, H.Z.; Lu, P.X. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. Biosci. Rep. 2019, 39.

34.

Shetzline, S.E.; Rallapalli, R.; Dowd, K.J.; Zou, S.M.; Nakata, Y.; Swider, C.R.; Kalota, A.; Choi, J.K.; Gewirtz, A.M. Neuromedin U: A Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004, 104, 1833–1840.

35.

Harding, M.A.; Theodorescu, D. RhoGDI2: A new metastasis suppressor gene: Discovery and clinical translation. Urol. Oncol. Semin. Orig. Investig. 2007, 25, 401–406.

36.

Wu, Y.; McRoberts, K.; Berr, S.S.; Frierson, H.F.; Conaway, M.; Theodorescu, D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007, 26, 765–773.

37.

Przygodzka, P.; Papiewska-Pajak, I.; Bogusz, H.; Kryczka, J.; Sobierajska, K.; Kowalska, M.A.; Boncela, J. Neuromedin U is upregulated by Snail at early stages of EMT in HT29 colon cancer cells. Biochim. Biophys. Acta Gen. Subj. 2016, 1860, 2445–2453.

38.

You, S.J.; Gao, L. Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses. Gene 2018, 678, 137–142.

39.

Martinez, V.G.; Crown, J.; Porter, R.K.; O’Driscoll, L. Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int. J. Cancer 2017, 140, 2771–2784.

40.

Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 2017, 7, 339–348, doi:10.15171/apb.2017.041.

and should be changed to the following ones:

23.

Yamashita, K.; Upadhyay, S.; Osada, M.; Hoque, M.O.; Xiao, Y.; Mori, M.; Sato, F.; Meltzer, S.J.; Sidransky, D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, 2, 485–495, doi:10.1016/S1535-6108(02)00215-5.

24.

Tokumaru, Y.; Yamashita, K.; Osada, M.; Nomoto, S.; Sun, D.I.; Xiao, Y.; Hoque, M.O.; Westra, W.H.; Califano, J.A.; Sidransky, D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004, 64, 5982–5987, doi:Doi 10.1158/0008-5472.Can-04-0993.

25.

Wang, L.; Chen, C.; Li, F.; Hua, Q.Q.; Chen, S.M.; Xiao, B.K.; Dai, M.Y.; Li, M.; Zheng, A.Y.; Yu, D.; et al. Overexpression of neuromedin U is correlated with regional metastasis of head and neck squamous cell carcinoma. Mol. Med. Rep. 2016, 14, 1075–1082, doi:10.3892/mmr.2016.5347.

26.

Ketterer, K.; Kong, B.; Frank, D.; Giese, N.A.; Bauer, A.; Hoheisel, J.; Korc, M.; Kleeff, J.; Michalski, C.W.; Friess, H. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett. 2009, 277, 72–81, doi:10.1016/j.canlet.2008.11.028.

27.

Shetzline, S.E.; Rallapalli, R.; Dowd, K.J.; Zou, S.M.; Nakata, Y.; Swider, C.R.; Kalota, A.; Choi, J.K.; Gewirtz, A.M. Neuromedin U: A Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004, 104, 1833–1840, doi:10.1182/blood-2003-10-3577.

28.

Harding, M.A.; Theodorescu, D. RhoGDI2: A new metastasis suppressor gene: Discovery and clinical translation. Urol. Oncol.-Semin. Ori. 2007, 25, 401–406, doi:10.1016/j.urolonc.2007.05.006.

29.

Wu, Y.; McRoberts, K.; Berr, S.S.; Frierson, H.F.; Conaway, M.; Theodorescu, D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007, 26, 765–773, doi:10.1038/sj.onc.1209835.

30.

Przygodzka, P.; Papiewska-Pajak, I.; Bogusz, H.; Kryczka, J.; Sobierajska, K.; Kowalska, M.A.; Boncela, J. Neuromedin U is upregulated by Snail at early stages of EMT in HT29 colon cancer cells. BBA-Gen. Subj. 2016, 1860, 2445–2453, doi:10.1016/j.bbagen.2016.07.012.

31.

You, S.J.; Gao, L. Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses. Gene 2018, 678, 137–142, doi:10.1016/j.gene.2018.08.032.

32.

Lin, T.Y.; Wu, F.J.; Chang, C.L.; Li, Z.Y.; Luo, C.W. NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling. Oncotarget 2016, 7, 10228–10242, doi:10.18632/oncotarget.7169.

33.

Yang, X.Y.; Wang, C.C.; Lee, W.Y.W.; Trovik, J.; Chung, T.K.H.; Kwong, J. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 2018, 413, 23–34, doi:10.1016/j.canlet.2017.10.028.

34.

Garczyk, S.; Klotz, N.; Szczepanski, S.; Denecke, B.; Antonopoulos, W.; Von Stillfried, S.; Knchel, R.; Rose, M.; Dahl, E. Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. Oncotarget 2017, 8, 36246–36265, doi:10.18632/oncotarget.16121.

35.

Martinez, V.G.; Crown, J.; Porter, R.K.; O’Driscoll, L. Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int. J. Cancer 2017, 140, 2771–2784, doi:10.1002/ijc.30705.

36.

Rani, S.; Corcoran, C.; Shiels, L.; Germano, S.; Breslin, S.; Madden, S.; McDermott, M.S.; Browne, B.C.; O’Donovan, N.; Crown, J.; et al. Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. Cancer Res. 2014, 74, 3821–3833, doi:10.1158/0008-5472.Can-13-2053.

37.

Harten, S.K.; Esteban, M.A.; Shukla, D.; Ashcroft, M.; Maxwell, P.H. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Mol. Cancer 2011, 10, 89.

38.

Zhang, S.L.; Wang, Q.; Han, Q.; Han, H.Z.; Lu, P.X. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. Bioscience Rep. 2019, 39, doi:10.1042/Bsr20190083.

39.

Alevizos, I.; Mahadevappa, M.; Zhang, X.; Ohyama, H.; Kohno, Y.; Posner, M.; Gallagher, G.T.; Varvares, M.; Cohen, D.; Kim, D.; et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001, 20, 6196–6204, doi:10.1038/sj.onc.1204685.

40.

Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 2017, 7, 339–348, doi:10.15171/apb.2017.041.

The Editorial Team would like to apologize for any inconvenience caused to the readers by these changes.